high mobility group box 1 pseudogene 23Genealiases: []
Q-omics provides the consensus-scored HMGB1P23 profile across patient tissues and cancer cell-line models. HMGB1P23 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, HMGB1P23 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, HMGB1P23 RNA expression shows 9,675 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UCS, KICH, and ESCA as cancer lineages where HMGB1P23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB1P23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB1P23 survival associations across molecular data types. HMGB1P23 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB1P23 RNA expression–survival associations across cancer types. High HMGB1P23 expression shows unfavorable associations in UCS, PAAD, CHOL and COAD, but favorable associations in KIRC and LAML. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for HMGB1P23 RNA expression.
This table summarizes HMGB1P23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB1P23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB1P23 shows lower tumor expression in BRCA and KIRC and higher tumor expression in KICH, STAD and THCA. The KICH box plot shows higher HMGB1P23 RNA expression in tumor versus normal tissue (log2 FC = +0.836, t-test p < 0.001).
This table shows molecular features associated with HMGB1P23 in patient tissues and cancer cell lines. In patient samples, HMGB1P23 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
